Drug Profile


Alternative Names: BBM 2478A; BMY 28090; Elsamicin A; NSC 369327; SPI-28090

Latest Information Update: 14 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Spectrum Pharmaceuticals
  • Class Aminoglycosides; Benzopyrans; Cytostatic antibiotics
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Apr 2016 No recent reports on development identified - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (IV)
  • 21 Apr 2011 Elsamitrucin is available for licensing in World (excluding USA) as of 21 Apr 2011. http://www.spectrumpharm.com/
  • 21 Apr 2011 Phase-I clinical trials in late-stage Solid tumours (in combination with paclitaxel) in USA (IV) before April 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top